Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results
James D. Bowen(Swedish Medical Center), RA Nash(University of Washington), Qingbo Guan(Shandong Provincial Hospital), Gretchen Henstorf(Fred Hutch Cancer Center), Mark H. Wener(University of Washington), Peter A. McSweeney(Mesoblast (United States)), B A McLaughlin(Fred Hutch Cancer Center), Harry Openshaw(City Of Hope National Medical Center), George H. Kraft(Patara Pharma (United States)), Kenneth R. Maravilla(University of Washington), S.Ž. Pavletić(National Cancer Institute), Annette Wundes(University of Washington Medical Center), R Storb, Ted Gooley(Fred Hutch Cancer Center)
Cited by 82
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease
|Nature Genetics|2011|2k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k